Aimmune Therapeutics, Inc.
DelistedCIK 1631650fmd_02QQXCR8X6EPQ1E3NSM4TK9VYDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2020, 27 periods
Latest annual · FY2019
Millions- Operating income
- (250)
- Net income
- (248)
- Free cash flow
- (203)
Latest quarter · Q2 FY2020
Millions- Total revenues
- 0
- Gross profit
- (5)
- Operating income
- (66)
- Net income
- (69)
- Free cash flow
- (127)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2014 to FY2019
- n/m
Aimmune Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Operating income | -$249.8 million | -$215.3 million | 10-K 2020-02-27 · proof | |
| Net income | -$248.5 million | -$210.8 million | 10-K 2020-02-27 · proof | |
| Cash from operating activities | -$195.4 million | -$169.1 million | 10-K 2020-02-27 · proof | |
| Free cash flow | -$203.5 million | -$178.5 million | 10-K 2020-02-27 · proof | |
| Total assets | $204.4 million | $339.6 million | -39.8% | 10-K 2020-02-27 · proof |
| Total liabilities | $100.3 million | $40.6 million | +147.1% | 10-K 2020-02-27 · proof |
| Cash and cash equivalents | $79.9 million | $107.5 million | -25.7% | 10-K 2020-02-27 · proof |
- What was Aimmune Therapeutics, Inc.'s operating income in fiscal 2019?
- Aimmune Therapeutics, Inc. reported operating income of -$249.8 million for fiscal 2019 (the year ended Dec 31, 2019), against -$215.3 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
- What was Aimmune Therapeutics, Inc.'s net income in fiscal 2019?
- Aimmune Therapeutics, Inc. reported net income of -$248.5 million for fiscal 2019 (the year ended Dec 31, 2019), against -$210.8 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
- What was Aimmune Therapeutics, Inc.'s cash from operating activities in fiscal 2019?
- Aimmune Therapeutics, Inc. reported cash from operating activities of -$195.4 million for fiscal 2019 (the year ended Dec 31, 2019), against -$169.1 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
- What was Aimmune Therapeutics, Inc.'s free cash flow in fiscal 2019?
- Aimmune Therapeutics, Inc. reported free cash flow of -$203.5 million for fiscal 2019 (the year ended Dec 31, 2019), against -$178.5 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
- What are Aimmune Therapeutics, Inc.'s total assets?
- As of Dec 31, 2019, Aimmune Therapeutics, Inc. reported total assets of $204.4 million, against $339.6 million a year earlier (-39.8%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
- What are Aimmune Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2019, Aimmune Therapeutics, Inc. reported total liabilities of $100.3 million, against $40.6 million a year earlier (+147.1%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
- What are Aimmune Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2019, Aimmune Therapeutics, Inc. reported cash and cash equivalents of $79.9 million, against $107.5 million a year earlier (-25.7%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1631650&period_type=annual&limit=5"Information only, not investment advice.